Beijing Peking University WBL Biotech Co., Ltd. (WPU) is a high-tech pharmaceutical joint-venture of Peking University, the Asiapharm Group Ltd of Singapore and the Beijing Enterprises Holdings Limited of Hong Kong, which was founded in 1994 with registered capital of RMB80 million. Our company mainly engages in the research, development, production and marketing of natural drugs and modern Chinese medicines.

Xuezhikang capsule (XZK), the lipid-regulating Chinese medicine, is a leading product of WPU. It is an extract from Red Yeast Rice (Hong Qu) and is highly effective in reducing bodys TC, TG, and LDL-C atherosclerosis index (AI) and elevating HDL-C level.

A randomized placebo-controlled trial, the Chinese Coronary Secondary Prevention Study (CCSPS), published in June 15 issue of the American Journal of Cardiology shows that, the long-term therapy with XZK significantly decreased the recurrence of coronary events. The IND application of XZK in the USA has been approved in September of 2008.